Pulmonary alveolar proteinosis in a cat
- 1.4k Downloads
Pulmonary alveolar proteinosis is an extremely rare lung disease in animals and humans. It is characterized by the deposition of a large amount of phospholipoproteinaceous material in the alveoli. There are several possible etiologies, both congenital and acquired. Alveolar macrophages play an important role in the clearance of surfactant. This is the first report of pulmonary alveolar proteinosis in the feline species.
Pulmonary alveolar proteinosis was diagnosed in an 8-month-old cat with chronic tachypnea, failure to thrive and finally respiratory distress. The diagnosis was based on the milky appearance of the bronchoalveolar lavage fluid taken under general anesthesia after bronchoscopy. Because of the worsening respiratory distress and development of anorexia the kitten was euthanized. Histopathology of the lungs showed alveoli and bronchi filled with eosinophilic material. Electron microscopy revealed lamellated intra-alveolar bodies. As the granulocyte-macrophage colony-stimulating factor was elevated in the serum and no autoantibodies against granulocyte-macrophage colony-stimulating factor were detected, a primary hereditary pulmonary alveolar proteinosis was suspected. The underlying cause was thought to be a dysfunction of the receptor of the granulocyte-macrophage colony-stimulating factor, however, a mutation in the genes encoding the alpha and beta chains of this receptor has not been found.
This is the first description of pulmonary alveolar protienosis in a cat. This kitten is thought to have a primary hereditary pulmonary alveolar proteinosis with a possible defect in the signalling pathway of the receptor of the granulocyte-macrophage colony-stimulating factor. The imaging and pathologic findings are similar to those of humans.
KeywordsBronchoalveolar lavage Cat Computed tomography scan Congenital Electron microscopy Energy dispersive X-ray analysis Granulocyte-macrophage colony-stimulating factor Lung Respiratory distress Surfactant
Bronchoalveolar lavage fluid
- CSF2RA and CSF2RB
Alpha and beta chains of the GM-CSF receptor
Energy dispersive X-ray analysis
Granulocyte-macrophage colony-stimulating factor
Human immunodeficiency virus
Pulmonary alveolar proteinosis
Periodic acid Schiff
Pulmonary alveolar proteinosis (PAP) is a rare lung disease in animals and humans. It is a heterogeneous group of conditions and characterized by deposition of a large amount of phospholipoproteinaceous material in the alveoli . The incidence in humans is up to 6 cases per 1,000,000 people . Though there are a few canine case reports of PAP [2, 3, 4], to the best of our knowledge PAP has not been described so far in the cat .
The main pathogenic mechanism of PAP is the insufficient clearance of the surfactant in the alveolar space, leading to its accumulation and consequent respiratory insufficiency . Surfactant is a surface-active lipoprotein complex that prevents alveolar collapse. It contains mostly phospholipids and 10 % proteins including surfactant protein A, B, C and D . Surfactant is produced by the alveolar type II epithelial cells, which are also responsible for its clearance together with alveolar macrophages [6, 7]. According to the most recent classification in human beings, PAP can be either primary or secondary . In addition to these groups a third group, the so called PAP-like diseases, has been described. Within the primary group, two forms have been identified: autoimmune and hereditary. Primary autoimmune PAP is characterized by the presence of antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) [7, 8, 9]. GM-CSF is essential for the differentiation and activation of alveolar macrophages and for the maintenance of surfactant homeostasis [6, 7, 10, 11]. Deficient alveolar macrophages lead to a reduced surfactant clearance. Primary hereditary PAP is due to gene mutations involving the beta or more rarely alpha chain of GM-CSF receptor, leading to the impairment of GM-CSF signaling [1, 10]. Secondary PAP is probably caused by factors that reduce the number or the function of alveolar macrophages . There are several conditions that can lead to secondary PAP in humans, such as inhalation exposure (e.g. silicon, cement, bakery flour, cleaning products), infectious diseases (such as HIV), amyloidosis, hematologic disorders (such as leukemias), other malignancies (such as adenocarcinoma), and various other disorders (such as lysinuric protein intolerance, severe combined immunodeficiency) [1, 12]. PAP-like diseases are due to genetic mutations that encode surfactant protein-B (SP-B) or SP-C leading to surfactant deficiency or abnormal production (oligomers and dimers), or a mutation of the gene encoding the membrane lipid transporter ABCA3 on type II pneumocytes, with accumulation of abnormal lamellar bodies [1, 10, 13, 14, 15, 16, 17]. The principal consequence is the gross distortion of lung structure due to widening of alveolar walls and extensive fibrosis . Macrophages are not primarily involved in the pathogenesis of PAP-like diseases; they appear foamy as the result of intra-alveolar accumulation of abnormal overproduced surfactant sub-forms (oligomers and dimers). This is in contrast to autoimmune PAP where surfactant is structurally and functionally normal but macrophages do not work properly. It is thought that abnormal surfactant (oligomers and dimers) cannot be completely digested by alveolar macrophages, but there is no clear evidence to prove this.
An 8-month-old female domestic shorthair kitten was referred to the Companion Animal Clinic of the Faculty of Veterinary Medicine of the Utrecht University because of chronic shortness of breath. Tachypnea and forced breathing was noticed since 3 months of age. This was the smallest kitten in the litter of four. The queen was imported from Morocco and was living in the Netherlands. The father was an unknown, presumably Dutch, stray cat. The queen and also her mother have always been clinically healthy. The presented kitten originated from the third litter of the queen.
Besides the slowly worsening respiratory distress the kitten developed a poor appetite and severe exercise intolerance. No cough or other clinical signs (including fever or signs of recurrent infections) were noticed. The kitten was living in a city center. The owner did not have any known potentially hazardous hobbies (such as painting). No possible exposure to inhalational environmental agents was identified during multiple interviews with the owner. Vaccinations and deworming were up-to-date.
At presentation the kitten was depressed, weak and showed tachypnea (60 breaths/min at rest) with a prolonged inspiration. The kitten was too small for its age and had a poorly kept hair coat and poor body condition, weighing 2.5 kg (5.5 lbs). Occasional wheezes were heard. Lung auscultation revealed increased respiratory sounds. The rest of the physical examination was unremarkable.
To further characterize the pulmonary disease a bronchoscopy was performed. The kitten was pretreated with subcutaneous terbutaline to prevent procedure-related bronchoconstriction as recommended by Johnson & Vernau . After premedication with acepromazine (50 μg/cat), methadone (500 μg/cat) and glycopyrrolate (25 μg/cat), general anesthesia was induced and maintained with intravenous propofol (0.15 mg/kg/min). Prior to induction of anesthesia oxygenation was performed by oxygen flow by. During the procedure oxygen was administered through the bronchoscope in a rate of 4 l/min. The kitten was breathing spontaneously and was not intubated, therefore also not ventilated during the procedure. Bronchoscopy with a 3-mm rigid scope did not show any obvious abnormalities, except when the instrument was pulled back, the bronchoscope retracted a thin whitish membrane from the bronchial wall. After completing the bronchoscopy a blind bronchoalveolar lavage was taken by injecting 5 ml of physiologic NaCl solution into a tertiary bronchus through an end-hole canine urinary catheter (50 cm with 2 mm outer diameter). Despite of oxygen enrichment the hemoglobin-saturation was never above 85 % during the bronchoscopy. After taking the bronchoalveolar lavage no expiratory CO2 was detected for about 90 s. The recovery from the anesthesia was prolonged, which made hospitalization necessary in an oxygen cage. An arterial blood gas analysis (when 40 % oxygen was inhaled) showed a severe hypoxemia (PO2 5.96 kPa). The next day the kitten’s clinical condition was comparable to the preanesthetic state and was discharged from the hospital. No medication was prescribed.
Based on the results of the above described investigations pulmonary alveolar proteinosis (PAP) was suspected [1, 2]. As this kitten had experienced respiratory problems since a very young age, a congenital anomaly was suspected. Because alveolar proteinosis has not yet been reported in the feline species and only a few case reports were found in the literature about dogs at the time of the clinical presentation [2, 3, 4, 5], besides a thorough literature search, a human pediatric pulmonologist was consulted so as to look for potentially curable underlying diseases. Therapeutic lung lavage, which is the treatment of choice in humans with alveolar proteinosis [1, 12, 19], was considered to be a technically challenging procedure with an unacceptably high risk and presumably fatal outcome, as the kitten almost died during the diagnostic bronchial wash.
A quantitative amino acid column chromatography was made from a plasma sample to look for metabolic diseases such as lysinuric protein intolerance, which is reported to be a rare underlying cause of alveolar pulmonary proteinosis, especially in Finnish children [1, 12]. This test showed no abnormalities in the concentrations of the following amino acids: taurine, asparagine acid, hydroxyl-proline, serine, asparagine, glutamic acid, glutamine, proline, glycine, alanine, citrulline, alpha-amino butyric acid, valine, cystine, methionine, isoleucine, leucine, tyrosine, phenylalanine, ornithine, histidine, lysine and arginine. The plasma lysine concentration was not decreased, and the urinary lysine concentration was not elevated either. As no reference ranges were known for the cat at the laboratory, the plasma samples of 3 other cats were compared to the patient’s sample. No obvious differences were detected between the values of the patient and the controls.
Because of the progressively worsening respiratory distress and the development of complete anorexia as well as the poor prognosis the owner decided to have the kitten euthanized one month after the bronchoscopy, at 9 months of age.
Although all the above-described findings confirm the diagnosis of pulmonary alveolar proteinosis , this is a heterogeneous group of disorders with several possible etiologies [1, 8]. To look for the possible cause a number of additional investigations were performed from the stored blood and BAL samples.
No autoantibodies against GM-CSF were found in the kitten’s plasma. Its concentration was less than 0.156 μg/ml (normal level in humans is less than 3 μg/ml). Because an assay for feline species was not commercially available, a human assay was used . Serum from an adult cat without respiratory signs was used as a negative control. No feline positive control is available.
GM-CSF was measured in the BAL (3.1 pg/ml) and in the serum (2.8 pg/ml) of the affected kitten. The GM-CSF concentration was also measured in the serum samples of 14 control cats, and was found to be less than 1 pg/ml in each of them.
Detected coding variants in the DNA of the alpha and beta chains of the Granulocyte-Macrophage Colony - Stimulating Factor receptor (CSF2RA and CSF2RB)
29 % A; 52 % R; 19 % G
34 % A; 7 % R; 59 % G
In the above-described young cat many potential disorders that may cause PAP have been excluded. Because of the absence of GM-CSF autoantibodies a primary autoimmune PAP can be excluded [7, 8]. The increased concentration of GM-CSF in the serum is compatible with a dysfunction of the GM-CSF receptor . Therefore, the genes encoding the alpha and beta chains of the GM-CSF receptor, and not those encoding SP or ABCA3, have been investigated. No mutation has been found that can lead to a dysfunction of this receptor. Because of the presence of intra-alveolar silicon in the BAL, secondary PAP due to silicon (and possibly arsenic) inhalation may also be possible [1, 22, 23]. However, due to the fact that the majority of urban cats in the Western countries come in contact with silicon through silicon-containing litter box filling on a daily basis  and so far no PAP has been reported in cats, a secondary PAP in the present kitten is unlikely. On the other hand, data on concentration or presence of silicon and arsenic particles in BAL of healthy cats are lacking, therefore we cannot state that the presence of these particles in the BAL is causative of PAP in this case or even harmful at all. This amount of intra-alveolar silicon may be a “normal” finding in cats in urban environment. The underlying defect which led to PAP in this kitten is thought to be present in the signalling pathway of the GM-CSF receptor.
Thanks to Dr. Jelke Jan Smit for referring the patient and to dr. Suzanne W. J. Terheggen-Lagro, dr. Coline van Moorsel and prof. dr. Jan Grutters for their advice during the investigations. The authors are grateful to dr. Peter M. van Hasselt for performing the amino acid analysis.
- 1.Bonella F, Theegarten D, Guzman J, Costabel U. Alveolar lipoproteinosis syndromes. Eur Respir Mon. 2011;54:171–86.Google Scholar
- 21.Hau J, Nilsson M, Skovgaard-Jensen H-J, De Souza A, Wandall LT. Analysis of animal serum proteins using antisera against human analogous proteins. Scand J Lab Anim Sci. 1990;17:3–7.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.